Canadian National Railway Stock Hits New 52-Week High (CNI)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Canadian National Railway (NYSE: CNI) hit a new 52-week high Thursday as it is currently trading at $91.88, above its previous 52-week high of $91.68 with 114,866 shares traded as of 11:03 a.m. ET. Average volume has been 676,100 shares over the past 30 days.

Canadian National Railway has a market cap of $38.85 billion and is part of the services sector and transportation industry. Shares are up 16.4% year to date as of the close of trading on Wednesday.

Canadian National Railway Company, together with its subsidiaries, engages in rail and related transportation business in North America. The company has a P/E ratio of 15.5, above the average transportation industry P/E ratio of 15 and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Canadian National Railway as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, impressive record of earnings per share growth, notable return on equity and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full Canadian National Railway Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing